What is Morgan Stanley's price target for AXSM?

Morgan Stanley's latest stated price target for Axsome Therapeutics Inc. (AXSM) is $204, from its action on Jan 8, 2026.

What is Morgan Stanley's rating on AXSM?

Morgan Stanley rates AXSM Equal-Weight, a neutral rating, as of Jan 8, 2026.

When did Morgan Stanley last change its view on AXSM?

On Jan 8, 2026, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $204.

Analyst firms · Morgan Stanley · AXSM

Morgan Stanley AXSM price target and rating history

Axsome Therapeutics Inc. (AXSM) · Health Care

Morgan Stanley rates Axsome Therapeutics Inc. (AXSM) Equal-Weight with a $204 price target, as of its latest action on Jan 8, 2026. It has published 4 rating actions on AXSM since August 2021, including 1 upgrade and 2 downgrades. Across 4 firms with a AXSM price target in the last 12 months, the median target is $257.50. Morgan Stanley's $204 is 21% below that.

Current rating: Equal-Weight
Price target: $204
Median target, all firms: $257.50
Actions on AXSM: 4

Morgan Stanley price target on AXSM

Morgan Stanley price target on AXSM, each point a stated target, August 2021 to January 2026.

Every Morgan Stanley rating on AXSM

Jan 8, 2026
DowngradeMorgan Stanley downgrades to Equal-Weight from Overweight, price target $204
Jul 3, 2025
ResumeMorgan Stanley resumes coverage at Overweight, price target $190
Apr 29, 2024
UpgradeMorgan Stanley upgrades to Overweight from Equal-Weight, price target $90 to $115
Aug 10, 2021
DowngradeMorgan Stanley downgrades to Equal-Weight from Overweight, price target $105 to $34

How other firms rate AXSM

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Truist Securities	Buy	$285	Sep 23, 2026
BMO Capital Markets	Outperform	$310	Jul 21, 2026
Wolfe Research	Outperform	$230	Feb 24, 2026
Morgan Stanley	Equal-Weight	$204	Jan 8, 2026

Questions about Morgan Stanley and AXSM

What is Morgan Stanley's price target for AXSM?: Morgan Stanley's latest stated price target for Axsome Therapeutics Inc. (AXSM) is $204, from its action on Jan 8, 2026.
What is Morgan Stanley's rating on AXSM?: Morgan Stanley rates AXSM Equal-Weight, a neutral rating, as of Jan 8, 2026.
When did Morgan Stanley last change its view on AXSM?: On Jan 8, 2026, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $204.
How does Morgan Stanley's AXSM target compare with other analysts?: Across 4 firms with a AXSM price target in the last 12 months, the median target is $257.50. Morgan Stanley's $204 is 21% below that.

More AXSM rating histories

All Morgan Stanley ratings AXSM news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.